PRINCETON, N.J. / Sep 01, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Giovanni Caforio, M.D., board chair and chief executive officer, and Chris Boerner, Ph.D., executive vice president and chief operating officer, will answer questions about the company during a fireside chat at 8 a.m. EDT.
Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following the session’s conclusion.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$48.28 |
| Daily Change: | 0.43 0.90 |
| Daily Volume: | 17,550,037 |
| Market Cap: | US$98.010B |
May 06, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
